CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery

NCT ID: NCT00925756

Last Updated: 2020-08-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-10-20
• Study Completion Date: 2014-04-11

Brief Summary

CCTG 590 is a open-label study to evaluate the impact of therapy intensification with Maraviroc (MVC) (a CCR5 inhibitor) to a stable suppressive HIV antiretroviral regimen on the rate of CD4+ T-cell recovery and gene expression profiles. Patients on a stable first-line HIV regimen with continued viral suppression and sub-optimal CD4+ T-cell counts will be eligible for this study. Those who are found to be eligible will have MVC (dose-adjusted to background HIV regimen) added to their current HIV regimen for 24 weeks. After the 24 week intensification, the MVC will be discontinued, the original antiretroviral regimen will be continued and the subjects will be followed for an additional 12 weeks.

The investigators hypothesize that MVC will improve the rate of CD4 recovery. This improved CD4 recovery will be associated with favorable changes in gene expression profiles of genes involved with CD4 maintenance and circulation.

Detailed Description

Blunted CD4+ T-cell responses during viral control may be a consequence of on-going T-cell destruction in the regenerative phase of CD4 recovery from activation-induced apoptosis and/or reduced production from decreased thymic output. Maraviroc, a CCR5 inhibitor, may improve the clinical status of HIV-infected by two distinct mechanisms. First, by blocking HIV entry into CD4+ T-cells, CCR5 inhibitors have direct antiviral activity. Second, as the pro-inflammatory state of HIV infection up-regulates CCR5 ligands and receptors, this CCR5 receptor antagonist may abrogate immune activation and resultant T-cell apoptosis. Importantly, MVC binds CCR5 receptors without inducing intracellular signaling or altering cell-surface expression. Potentially, MVC intensification during viral suppression with ART may further decrease persistent activation-induced apoptosis and improve repair and remodeling of lymphoid tissue leading to increased CD4+ T-cell recovery and function.

The aim of this study is to evaluate a potentially therapeutic immunomodulatory effect of MVC. Several measures of immune homeostasis will be determined in this study, including functional genomic analysis and extended T-cell phenotyping. Genes responsive to MVC therapy will be identified and categorized into functional groups. Based upon existing literature of the identified genes and observed immune responses (change in CD4/CD8 subsets) during MVC therapy, a model of CCR5 responsive-genes and potential impact on immune recovery will be outlined. Potentially, individuals experiencing immune discordance during suppressive ART may be better treated by MVC antiretroviral intensification.

1. We hypothesize that expression will decrease among genes involved in immune activation (NF-kB, MAPK, nuclear factor of activated T-cells, MYD88 and STAT1), apoptosis (Fas ligand and TRAIL) and trafficking/repopulation of T-cells (CCR5, MIP-1α, MIP-1β and RANTES) and increase among genes involved in tissue repair (platelet-derived growth factor, insulin-like growth proteins and osteoblast-specific transcription factor).

1. The gene expression profiles induced by MVC will be associated with a favorable increase in the rate of CD4+ T-cell recovery.

2. The rate of CD4 recovery (cells/month) will be greater during MVC compared to before.

3. The proportion of cells expressing activation/ apoptosis markers will decrease from baseline and this decrease will be associated with improved CD4 recovery.

4. The proportion of naïve cells will increase from baseline and this increase will be associated with improved CD4 recovery.

5. The rate of CD4 recovery will be greater among those subjects receiving PI-containing treatment regimens compared to those receiving NNRTI-containing treatment regimen.

Conditions

HIV Infections

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Maraviroc 150 mg, 300 mg, or 600 mg twice daily

This was a single arm study where Maraviroc was added for 24 weeks.

Maraviroc was dose-adjusted for concomitantly administered HIV medications according to the manufacture's recommendations:

150 mg twice daily with strong CYP3A4 inhibitors, including:

• Protease inhibitors (except tipranavir/ ritonavir)
• Delavirdine
• ketoconazole, itraconazole, clarithromycin, nefazadone, telithromycin
• Darunavir/r + etravirine

300 mg twice daily with non-inducers/ non-inhibitors of CYP3A4, including:

• Tipranavir/ ritonavir
• Nevirapine
• All NRTIs
• Enfuvirtide

600 mg twice daily with strong CYP3A4 inducers, including:

• Efavirenz, etravirine
• rifampin

Group Type: EXPERIMENTAL

Maraviroc

Intervention Type: DRUG

Maraviroc will be given dose-adjusted to background HIV treatment (150 mg, 300 mg, or 600 mg twice daily)

Interventions

Maraviroc

Maraviroc will be given dose-adjusted to background HIV treatment (150 mg, 300 mg, or 600 mg twice daily)

Intervention Type: DRUG

Other Intervention Names

Selzentry

Eligibility Criteria

Inclusion Criteria

1. HIV-1 infection

2. All available CD4+ T cell counts within the last 12 months of screening below 350 cells/mm3 (minimum of 3 values obtained > 30 days apart).

3. HIV treatment with a stable (for at least 6 months) antiretroviral regimen consisting of at least 2 NRTIs and either a protease inhibitor boosted with low dose ritonavir or an NNRTI. A stable regimen is defined as no additions or deletions for more than 14 cumulative days.

4. Patient considered to be receiving initial HIV regimen (history of medication substitution for toxicity is allowed).

5. All available plasma HIV RNA levels within the last 12 months are below the level of detection. Isolated values that are detectable but < 1000 copies will be allowed as long as the plasma HIV RNA levels before and after this detectable time point are undetectable - The subject should have a minimum of 3 values obtained > 30 days apart.

6. Females of childbearing potential must have a negative serum pregnancy test at screening and agree to use a double-barrier method of contraception throughout the study period.

7. Men and women age ≥ 18 years.

Exclusion Criteria

1. Current antiretroviral regimen contains tenofovir disoproxil fumarate AND didanosine in combination.

2. History of chronic hepatitis C (defined as HCV antibody positive and HCV RNA detectable).

3. History of chronic active hepatitis B (defined as surface antibody negative, surface antigen positive and HBV DNA detectable).

4. Concurrent use of G-CSF or GM-CSF.

5. Prior or concurrent use of IL-2.

6. Prior or concurrent use of a CCR5 inhibitor.

7. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.

8. Use of any immunomodulator, HIV vaccine, or investigational therapy within 30 days of study entry.

9. Use of human growth hormone within 30 days prior to study entry.

10. Initiation of testosterone or anabolic steroids within 30 days prior to study entry. (Exception: Chronic replacement dosages in patient's with diagnosed hypogonadism is allowed).

11. Evidence of splenic sequestration or suppressed bone marrow function:

• Clinical or radiographic evidence of significant splenomegaly.
• History of leukemia or lymphoma.
• History of myelosuppressive chemotherapy or irradiation

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of California, Los Angeles

OTHER

Sponsor Role: collaborator

University of Southern California

OTHER

Sponsor Role: collaborator

Pfizer

INDUSTRY

Sponsor Role: collaborator

California HIV/AIDS Research Program

OTHER

Sponsor Role: collaborator

University of California, San Diego

OTHER

Sponsor Role: lead

Responsible Party

Sheldon Morris

Clinical Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Sheldon Morris, MD

Role: STUDY_CHAIR

UC San Diego AntiViral Research Center (AVRC)

Richard Haubrich, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Diego

Locations

University Southern California

Los Angeles, California, United States

University California San Diego

San Diego, California, United States

Harbor-UCLA

Torrance, California, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

CCTG 590

Identifier Type: -

Identifier Source: org_study_id